Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 4: Formylation–Cyclization as a Flow–Batch Process Leads to Significant Improvements in Process Mass Intensity (PMI) and CO Generated versus the Batch–Batch Process
Gefapixant citrate (MK-7264) is a P2X3 antagonist for the treatment of chronic cough. The second generation manufacturing route developed for the Step 3A/3B formylation–cyclization reaction to generate the key intermediate diaminopyrimidine (1) (AF-072) required a significant excess of ethyl formate...
Saved in:
Published in | Organic process research & development Vol. 24; no. 11; pp. 2478 - 2490 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
WASHINGTON
American Chemical Society
20.11.2020
Amer Chemical Soc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Gefapixant citrate (MK-7264) is a P2X3 antagonist for the treatment of chronic cough. The second generation manufacturing route developed for the Step 3A/3B formylation–cyclization reaction to generate the key intermediate diaminopyrimidine (1) (AF-072) required a significant excess of ethyl formate (EF), potassium tert-butoxide (KOt-Bu), and guanidine•HCl (G•HCl) when both steps were run as batch processes. It was imperative to develop an alternative process that required less of each reagent and generated less carbon monoxide byproducts, as the annual production of the final active pharmaceutical ingredient (API) is expected to be over 50 MT. In addition, the second generation process was misaligned with our company’s strategy of having the best science in place at the first regulatory filing. The final flow–batch process described herein, which features a flow-based formylation combined with a batch cyclization, has been performed on a 500 kg scale and now requires 35% less EF (leading to a 70% reduction in waste carbon monoxide), 38% less KOt-Bu, and 50% less G•HCl. These improvements, along with a twofold increase in concentration, have resulted in a 54% reduction in the step process mass intensity (step-PMI) from the second generation two-step batch–batch process (PMI of 17.16) to the flow–batch process (PMI of 7.86), without sacrificing reaction performance. |
---|---|
AbstractList | Gefapixant citrate (MK-7264) is a P2X3 antagonist for the treatment of chronic cough. The second generation manufacturing route developed for the Step 3A/3B formylation–cyclization reaction to generate the key intermediate diaminopyrimidine (1) (AF-072) required a significant excess of ethyl formate (EF), potassium tert-butoxide (KOt-Bu), and guanidine•HCl (G•HCl) when both steps were run as batch processes. It was imperative to develop an alternative process that required less of each reagent and generated less carbon monoxide byproducts, as the annual production of the final active pharmaceutical ingredient (API) is expected to be over 50 MT. In addition, the second generation process was misaligned with our company’s strategy of having the best science in place at the first regulatory filing. The final flow–batch process described herein, which features a flow-based formylation combined with a batch cyclization, has been performed on a 500 kg scale and now requires 35% less EF (leading to a 70% reduction in waste carbon monoxide), 38% less KOt-Bu, and 50% less G•HCl. These improvements, along with a twofold increase in concentration, have resulted in a 54% reduction in the step process mass intensity (step-PMI) from the second generation two-step batch–batch process (PMI of 17.16) to the flow–batch process (PMI of 7.86), without sacrificing reaction performance. Gefapixant citrate (MK-7264) is a P2X3 antagonist for the treatment of chronic cough. The second generation manufacturing route developed for the Step 3A/3B formylation-cyclization reaction to generate the key intermediate diaminopyrimidine (1) (AF-072) required a significant excess of ethyl formate (EF), potassium tert-butoxide (KOt-Bu), and guanidine center dot HCl (G center dot HCl) when both steps were run as batch processes. It was imperative to develop an alternative process that required less of each reagent and generated less carbon monoxide byproducts, as the annual production of the final active pharmaceutical ingredient (API) is expected to be over 50 MT. In addition, the second generation process was misaligned with our company's strategy of having the best science in place at the first regulatory filing. The final flow-batch process described herein, which features a flow-based formylation combined with a batch cyclization, has been performed on a 500 kg scale and now requires 35% less EF (leading to a 70% reduction in waste carbon monoxide), 38% less KOt-Bu, and 50% less G center dot HCl. These improvements, along with a twofold increase in concentration, have resulted in a 54% reduction in the step process mass intensity (step-PMI) from the second generation two-step batch-batch process (PMI of 17.16) to the flow-batch process (PMI of 7.86), without sacrificing reaction performance. |
Author | Burris, Matthew Maloney, Kevin M Naber, John R Stone, Kevin Nappi, Jarod Ren, Hong Spencer, Glenn Jellett, Lisa Corcoran, Emily B Otte, Douglas A. L Basu, Kallol Donoghue, David Arvary, Rebecca A Whittington, Michael |
AuthorAffiliation | MSD Ballydine, MSD (Ireland) Ltd., Co |
AuthorAffiliation_xml | – name: MSD Ballydine, MSD (Ireland) Ltd., Co |
Author_xml | – sequence: 1 givenname: Douglas A. L orcidid: 0000-0002-4700-2842 surname: Otte fullname: Otte, Douglas A. L email: douglas.otte@merck.com – sequence: 2 givenname: Kallol orcidid: 0000-0002-4784-6068 surname: Basu fullname: Basu, Kallol – sequence: 3 givenname: Lisa surname: Jellett fullname: Jellett, Lisa – sequence: 4 givenname: Michael surname: Whittington fullname: Whittington, Michael – sequence: 5 givenname: Glenn surname: Spencer fullname: Spencer, Glenn – sequence: 6 givenname: Matthew surname: Burris fullname: Burris, Matthew – sequence: 7 givenname: Emily B surname: Corcoran fullname: Corcoran, Emily B – sequence: 8 givenname: Kevin surname: Stone fullname: Stone, Kevin – sequence: 9 givenname: Jarod surname: Nappi fullname: Nappi, Jarod – sequence: 10 givenname: Rebecca A surname: Arvary fullname: Arvary, Rebecca A – sequence: 11 givenname: David surname: Donoghue fullname: Donoghue, David organization: MSD Ballydine, MSD (Ireland) Ltd., Co – sequence: 12 givenname: Hong orcidid: 0000-0002-0754-7282 surname: Ren fullname: Ren, Hong – sequence: 13 givenname: Kevin M orcidid: 0000-0003-1422-5422 surname: Maloney fullname: Maloney, Kevin M – sequence: 14 givenname: John R orcidid: 0000-0002-4390-3467 surname: Naber fullname: Naber, John R |
BookMark | eNqNUU9v0zAUD2hIbGN3jj5ughTHrZOUGwRaKlqt0nbgFj07z5un1I5sp6Oc-A58Qz4JTjv1gITExX7Per8_fr-z5MRYg0nyOqOjjLLsHUg_sp1rRlRSyjh7npxmnNGUl_m3k1jTcpzmWU5fJmfeP1BKeZ6x02cXn3CLre02aAKxigCZO0RDwDTkpvcBtAHRIlmB6RXI0Dtt7sjaWYneE2UdmaOCTn-HiK90cBCQXK6-pgXLJ1dkDS6QyXsys26zayFoa37__FXtZKt_7DsCPmrOWvsY3z9CkPdH8iVC40mw5EbfGa20HCQWm87ZLQ52PdHmOLyCeCxMQON12JHL9Wpxtf9EdR0dGhx8NWSLzveR8x7JXutvzVfJCwWtx4un-zy5nX2-rb6ky-v5ovqwTIGVNKQglKQcBTJUqskkAygYy6nIgapMCJRTVgrO5YQXqARvBOYI44YXueLlZHye0AOtdNZ7h6runN6A29UZrYc065hmPaRZP6UZIeUB8ojCKi81GolH2BDnlE3LyTRWtIg57Jdb2d6ECH3z_9A4_fYwPVh4sL0zcRH_9vUH6FTOMg |
CitedBy_id | crossref_primary_10_1039_D2RE00256F crossref_primary_10_1021_acs_oprd_3c00510 crossref_primary_10_1021_acs_oprd_0c00241 crossref_primary_10_1016_j_crgsc_2022_100324 crossref_primary_10_1021_acs_oprd_0c00246 crossref_primary_10_1021_acs_oprd_0c00247 crossref_primary_10_1021_acs_oprd_0c00248 crossref_primary_10_1016_j_cogsc_2021_100562 crossref_primary_10_1021_acs_jmedchem_3c02374 crossref_primary_10_1021_acs_oprd_3c00395 crossref_primary_10_1021_acscatal_3c04565 crossref_primary_10_1016_j_cogsc_2022_100689 crossref_primary_10_1021_acs_oprd_2c00313 |
Cites_doi | 10.1021/acs.oprd.0c00247 10.1021/acssuschemeng.7b03360 10.1021/acs.oprd.8b00063 10.1039/c6gc02359b 10.1021/acs.oprd.0c00248 10.1021/acs.oprd.0c00241 10.1021/acs.oprd.0c00260 10.1016/j.tetlet.2009.06.140 10.1021/acs.oprd.0c00246 10.1021/ja00002a059 10.1039/C6GC02359B |
ContentType | Journal Article |
Copyright | 2020 American Chemical Society |
Copyright_xml | – notice: 2020 American Chemical Society |
DBID | 1KN AOWDO BLEPL DTL AAYXX CITATION |
DOI | 10.1021/acs.oprd.0c00252 |
DatabaseName | Current Chemical Reactions Web of Science - Science Citation Index Expanded - 2020 Web of Science Core Collection Science Citation Index Expanded CrossRef |
DatabaseTitle | Web of Science CrossRef |
DatabaseTitleList | Web of Science |
Database_xml | – sequence: 1 dbid: 1KN name: Current Chemical Reactions url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.CCR sourceTypes: Enrichment Source Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering Chemistry |
EISSN | 1520-586X |
EndPage | 2490 |
ExternalDocumentID | 10_1021_acs_oprd_0c00252 000592984900007 c340082981 |
GroupedDBID | 123 55A 5VS 7~N AABXI ABMVS ABUCX ACGFS ACS AEESW AENEX AFEFF ALMA_UNASSIGNED_HOLDINGS AQSVZ CS3 DU5 EBS ED ED~ F5P GNL IH9 JG JG~ RNS ROL UI2 VF5 VG9 W1F X XKZ -~X 1KN 4.4 ABJNI ABQRX ADHLV AHGAQ BAANH BLEPL CUPRZ DTL GGK GROUPED_WOS_WEB_OF_SCIENCE AAYXX CITATION |
ID | FETCH-LOGICAL-a280t-abfc05ebe2effd1c2aa72260b6a0f1bbec928b55c457efb5dbe6ea3d576f5843 |
IEDL.DBID | ACS |
ISICitedReferencesCount | 10 |
ISICitedReferencesURI | https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000592984900007 |
ISSN | 1083-6160 |
IngestDate | Fri Dec 06 02:12:25 EST 2024 Fri Dec 13 18:09:08 EST 2024 Wed Sep 18 01:16:12 EDT 2024 Tue Nov 24 15:57:34 EST 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | formylation green chemistry PMI process mass intensity flow chemistry CHEMISTRY |
Language | English |
License | https://doi.org/10.15223/policy-029 https://doi.org/10.15223/policy-037 https://doi.org/10.15223/policy-045 |
LinkModel | DirectLink |
LogoURL | https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg |
MergedId | FETCHMERGED-LOGICAL-a280t-abfc05ebe2effd1c2aa72260b6a0f1bbec928b55c457efb5dbe6ea3d576f5843 |
ORCID | 0000-0002-4784-6068 0000-0003-1422-5422 0000-0002-4700-2842 0000-0002-4390-3467 0000-0002-0754-7282 0000-0002-4100-2842 |
PageCount | 13 |
ParticipantIDs | acs_journals_10_1021_acs_oprd_0c00252 crossref_primary_10_1021_acs_oprd_0c00252 webofscience_primary_000592984900007CitationCount webofscience_primary_000592984900007 |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 XKZ 7~N VG9 W1F ACS AEESW AFEFF ABMVS ABUCX IH9 AQSVZ ED~ UI2 |
PublicationCentury | 2000 |
PublicationDate | 20201120 2020-11-20 |
PublicationDateYYYYMMDD | 2020-11-20 |
PublicationDate_xml | – month: 11 year: 2020 text: 20201120 day: 20 |
PublicationDecade | 2020 |
PublicationPlace | WASHINGTON |
PublicationPlace_xml | – name: WASHINGTON |
PublicationTitle | Organic process research & development |
PublicationTitleAbbrev | ORG PROCESS RES DEV |
PublicationTitleAlternate | Org. Process Res. Dev |
PublicationYear | 2020 |
Publisher | American Chemical Society Amer Chemical Soc |
Publisher_xml | – name: American Chemical Society – name: Amer Chemical Soc |
References | Maloney, KM (WOS:000592984900009) 2020; 24 Niknam, K (WOS:000269051700011) 2009; 50 Li, J (WOS:000391728900015) 2017; 19 Peng, F (WOS:000592984900005) 2020; 24 Andraos, J (WOS:000427092900045) 2018; 6 Levesque, F (WOS:000442453600010) 2018; 22 Di Maso, MJ (WOS:000592984900008) 2020; 24 MYERS, AG (WOS:A1991ET68200059) 1991; 113 Ren, H (WOS:000592984900004) 2020; 24 Basu, K (WOS:000592984900006) 2020; 24 ref6/cit6 ref1/cit1e ref1/cit1d ref5/cit5 ref1/cit1a ref4/cit4 ref1/cit1c ref1/cit1b ref3/cit3b ref3/cit3a |
References_xml | – volume: 113 start-page: 694 year: 1991 ident: WOS:A1991ET68200059 article-title: ENANTIOSELECTIVE SYNTHESIS OF THE EPOXY DIYNE CORE OF NEOCARZINOSTATIN CHROMOPHORE publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY contributor: fullname: MYERS, AG – volume: 24 start-page: 2491 year: 2020 ident: WOS:000592984900008 article-title: Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264). Part 5: Completion of the API Free Base via a Direct Chlorosulfonylation Process publication-title: ORGANIC PROCESS RESEARCH & DEVELOPMENT doi: 10.1021/acs.oprd.0c00247 contributor: fullname: Di Maso, MJ – volume: 6 start-page: 3206 year: 2018 ident: WOS:000427092900045 article-title: Useful Tools for the Next Quarter Century of Green Chemistry Practice: A Dictionary of Terms and a Data Set of Parameters for High Value Industrial Commodity Chemicals publication-title: ACS SUSTAINABLE CHEMISTRY & ENGINEERING doi: 10.1021/acssuschemeng.7b03360 contributor: fullname: Andraos, J – volume: 22 start-page: 1015 year: 2018 ident: WOS:000442453600010 article-title: Advancing Flow Chemistry Portability: A Simplified Approach to Scaling Up Flow Chemistry publication-title: ORGANIC PROCESS RESEARCH & DEVELOPMENT doi: 10.1021/acs.oprd.8b00063 contributor: fullname: Levesque, F – volume: 19 start-page: 127 year: 2017 ident: WOS:000391728900015 article-title: A data-driven strategy for predicting greenness scores, rationally comparing synthetic routes and benchmarking PMI outcomes for the synthesis of molecules in the pharmaceutical industry publication-title: GREEN CHEMISTRY doi: 10.1039/c6gc02359b contributor: fullname: Li, J – volume: 24 start-page: 2445 year: 2020 ident: WOS:000592984900004 article-title: Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 1: Introduction and Process Overview publication-title: ORGANIC PROCESS RESEARCH & DEVELOPMENT doi: 10.1021/acs.oprd.0c00248 contributor: fullname: Ren, H – volume: 24 start-page: 2453 year: 2020 ident: WOS:000592984900005 article-title: Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 2: Development of a Robust Process for Phenol Synthesis publication-title: ORGANIC PROCESS RESEARCH & DEVELOPMENT doi: 10.1021/acs.oprd.0c00241 contributor: fullname: Peng, F – volume: 24 start-page: 2498 year: 2020 ident: WOS:000592984900009 article-title: Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264). Part 6: Development of an Improved Commercial Salt Formation Process publication-title: ORGANIC PROCESS RESEARCH & DEVELOPMENT doi: 10.1021/acs.oprd.0c00260 contributor: fullname: Maloney, KM – volume: 50 start-page: 5210 year: 2009 ident: WOS:000269051700011 article-title: Silica-bonded N-propyl sulfamic acid as an efficient catalyst for the formylation and acetylation of alcohols and amines under heterogeneous conditions publication-title: TETRAHEDRON LETTERS doi: 10.1016/j.tetlet.2009.06.140 contributor: fullname: Niknam, K – volume: 24 start-page: 2462 year: 2020 ident: WOS:000592984900006 article-title: Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 3: Development of a One-Pot Formylation-Cyclization Sequence to the Diaminopyrimidine Core publication-title: ORGANIC PROCESS RESEARCH & DEVELOPMENT doi: 10.1021/acs.oprd.0c00246 contributor: fullname: Basu, K – ident: ref1/cit1d doi: 10.1021/acs.oprd.0c00247 – ident: ref1/cit1c doi: 10.1021/acs.oprd.0c00246 – ident: ref3/cit3b doi: 10.1021/acssuschemeng.7b03360 – ident: ref6/cit6 doi: 10.1021/acs.oprd.8b00063 – ident: ref5/cit5 doi: 10.1016/j.tetlet.2009.06.140 – ident: ref1/cit1a doi: 10.1021/acs.oprd.0c00248 – ident: ref1/cit1b doi: 10.1021/acs.oprd.0c00241 – ident: ref4/cit4 doi: 10.1021/ja00002a059 – ident: ref3/cit3a doi: 10.1039/C6GC02359B – ident: ref1/cit1e doi: 10.1021/acs.oprd.0c00260 |
SSID | ssj0005612 |
Score | 2.4003108 |
Snippet | Gefapixant citrate (MK-7264) is a P2X3 antagonist for the treatment of chronic cough. The second generation manufacturing route developed for the Step 3A/3B... |
Source | Web of Science |
SourceID | crossref webofscience acs |
SourceType | Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 2478 |
SubjectTerms | Chemistry Chemistry, Applied Chemistry, Organic Physical Sciences Science & Technology |
Title | Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 4: Formylation–Cyclization as a Flow–Batch Process Leads to Significant Improvements in Process Mass Intensity (PMI) and CO Generated versus the Batch–Batch Process |
URI | http://dx.doi.org/10.1021/acs.oprd.0c00252 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000592984900007 |
Volume | 24 |
WOS | 000592984900007 |
WOSCitedRecordID | wos000592984900007 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEDaoHKCqeBQqlpfmUKTuIUvidR7LDSKWAgpU2iL1FvnZrlolFcmqLCf-A_-QX8LYcXeXUqG9Wo7tyGPPN56ZbwjZzWwJW57ygCrDAhbHcYAoXAVKhirVwuiuZmTxOdn_yj4exUdLmpyrHnwaveKyGdSWDTGUVkHjdXuLpmh9WxiUT5bhHIn3bGZDNIeS0LskrxvBKiLZ_KWIrlE6TsGM73WVihrHS2jjSk4Hs1YM5I9_WRvXWPt9ctfjTHjTCcYDclNX2-R2flnebZtsrjARPryxtRI8BLUBDi4gB3ilYLLMsYKCVzObC-GSG8FnGQACX3ivDT-ffseNgnzqKG9hr_gUpAiF-nCAAgrsNYwRIc-76LvfP3_lc3nm00CBNzjn-Ky-wPa3qB5OFoPbIqANtDVMpseVDWyyU3RvIe5ps4FptehcoC0APiy_ncPeQfGh734i_wIdwzYibLChKDMc80SDm-vqnI_I4fjdYb4f-EoRAadZ2AZcGBnGKI9UG6MiSTlPEVeGIuGhiQTK6YhmIo4li1NtRKyETjQfKjS2DCKw4Q7ZqOpKPyZA0WZPRipj-AnaujLLmJRM2rJdQsgw6ZGXuKmlP-hN6Xz4NCpto93p0u90j_Qvpas873hD_tN3d1X8Fv0deQ4dZWzkHM49Eq3TLffc7pbToH2y5nKfkjvUPiREEV6bz8hG-22mnyPaasULd8z-ADrRKvE |
link.rule.ids | 314,780,784,2765,27076,27924,27925,56738,56788 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEDZVOZSq4lFasTznUKTuIW2SjZMsN4hYtrQpFbtIvUV-tiuqbNVkBcuJ_8A_5JcwdrwPqgqVq-XYjjz2fOOZ-YaQndSUsGUJ80KpIy-ilHqIwqUnhS8TxbVqakbmx3H_S_TxlJ6ukGCWC4OLqHCkyjrxF-wCwb5tM6SIvjB6Gm_du9RUrDRoKBssojpi5-BMO2gVxb7zTN40gtFHovpLH92ge6ye6T0gn-crtOElX_cmNd8TP66RN_7XLzwk9x3qhLeNmDwiK6rcJGvZrNjbJllf4iV8fGdjKZQIxhoY2PAcYKWEwSLjCnJWTkxmhE11BJdzAAiD4YPS7HL0HbcNspElwIXd_NBLEBi14QTFFaI30EO8PG1i8X7__JVNxYVLCgVW4Zy9i_E3bH-HyuJ8PrgpCVpBPYbB6Kw0YU5miuZlxD50VjAq551ztAzABenXU9g9yQ_a9ieyT9DwbSPeBhOYMsExzxXYua7PuUWGvffDrO-5uhEeC1O_9hjXwqconaHSWgYiZCxBlOnzmPk64Ci13TDllIqIJkpzKrmKFetINL004rHONlktx6V6QiBECz7uyjTCT9DyFWkaCREJU8SLc-HHLfIaN7Vwx74qrEc_DArTaHa6cDvdIu2ZkBWXDYvIP_ruLEvhvL-l0gm7adS17ucWCW7TLXNM74bhoH56y-W-Imv9YX5UHB0cHz4j90LzxBAEeKE-J6v11US9QBxW85f25P0Bw1szXg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEDZVkYAK8SggluccitQ9pCTZOMlyK4HQUlJW2oJ6i_ykK6rsqsmqXU78B_4hv4Sx490uVYXK1XJsRx57ZjzffEPIRmpK2LKEeaHUkRdRSj20wqUnhS8TxbVqa0YW-_HOl-jjIT1cIXSeC4OLqHGk2gbxzameSO0YBoLXtt0QI_rC6Gq8ea9TvGwNkms7G54jO2IX5Ex76BnFvotOXjaC0Umi_ksnXaJ_rK7J75Kvi1VaiMn3rWnDt8SPCwSO__0b98gdZ33Cdisu98mKqtbJzWxe9G2drC3xEz64dnsJUgRjDQwsTAdYJWF4nnkFBaumJkPCpjyCyz0ANIfhg9JsMjrD7YNsZIlwYbPY8xI0kLowQLGF6A3kaDfPWkze75-_spk4dsmhwGqcMz8en2L7W1QaR4vBTWnQGpoxDEffKgN3MlO0LyT2wbOGUbXoXKCHAA6s38xgc1Dsdu1PZJ-h5d1GuxsMQGWKYx4psHNdnPMhOcjfH2Q7nqsf4bEw9RuPcS18ilIaKq1lIELGErQ2fR4zXwccpbcfppxSEdFEaU4lV7FiPYkumEa7rPeIrFbjSj0mEKInH_dlGuEn6AGLNI2EiIQp5sW58OMOeYWbWrrjX5c2sh8GpWk0O126ne6Q7lzQyknLJvKPvhvLkrjobyl1wn4a9W0YukOCq3TLHOO7YTponlxxuS_JjcG7vPy0u7_3lNwKzUtDEOC9-oysNidT9RzNsYa_sIfvD2TANeE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+a+Green+and+Sustainable+Manufacturing+Process+for+Gefapixant+Citrate+%28MK-7264%29+Part+4%3A+Formylation-Cyclization+as+a+Flow-Batch+Process+Leads+to+Significant+Improvements+in+Process+Mass+Intensity+%28PMI%29+and+CO+Generated+versus+the+Batch-Batch+Process&rft.jtitle=Organic+process+research+%26+development&rft.au=Otte%2C+Douglas+A.+L.&rft.au=Basu%2C+Kallol&rft.au=Jellett%2C+Lisa&rft.au=Whittington%2C+Michael&rft.date=2020-11-20&rft.pub=Amer+Chemical+Soc&rft.issn=1083-6160&rft.eissn=1520-586X&rft.volume=24&rft.issue=11&rft.spage=2478&rft.epage=2490&rft_id=info:doi/10.1021%2Facs.oprd.0c00252&rft.externalDBID=n%2Fa&rft.externalDocID=000592984900007 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-6160&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-6160&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-6160&client=summon |